How many drugs treat Positron emission tomography?

Drug Landscape tracks 10 marketed treatments for Positron emission tomography (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/positron-emission-tomography.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Positron emission tomography — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Positron emission tomography (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Positron emission tomography, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Gallium Oxydatum	GALLIUM	Novartis		Glutamate carboxypeptidase 2, Prostate-specific antigen	2025-01-01
Posluma	FLOTUFOLASTAT F-18 GALLIUM	Blue Earth	Radioactive Diagnostic Agent [EPC]	Glutamate carboxypeptidase 2	2023-01-01
Detectnet	copper dotatate Cu-64	Radiomedix	Radioactive Diagnostic Agent [EPC]	somatostatin receptors, particularly SSTR2	2020-01-01
Cerianna	FLUOROESTRADIOL F-18	GE HealthCare	Radioactive Diagnostic Agent [EPC]	Estrogen receptor	2020-01-01
Tauvid	FLORTAUCIPIR F 18	Avid Radiopharms Inc		Microtubule-associated protein tau	2020-01-01
Fluorodopa F18	fluorodopa (18F)	Feinstein	fluorodopa (18F)		2019-01-01
Rubidium Bromatum	RUBIDIUM	Jubilant			2016-01-01
Axumin	fluciclovine (18F)	Blue Earth Diagnostics Ltd	Radioactive Diagnostic Agent [EPC]		2016-01-01
Neuraceq	FLORBETABEN F18	Piramal Imaging	Radioactive Diagnostic Agent [EPC]	Amyloid beta A4 protein	2014-01-01
Vizamyl	Flutemetamol (18F)	GE HealthCare	Radioactive Diagnostic Agent [EPC]	Amyloid beta A4 protein	2013-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

GE HealthCare · 2 drugs in Positron emission tomography
Avid Radiopharms Inc · 2 drugs in Positron emission tomography
Blue Earth Diagnostics Ltd · 1 drug in Positron emission tomography
Bracco · 1 drug in Positron emission tomography
Feinstein · 1 drug in Positron emission tomography
Invicro · 1 drug in Positron emission tomography
Jubilant · 1 drug in Positron emission tomography
Mayo Clinic · 1 drug in Positron emission tomography
Novartis · 1 drug in Positron emission tomography
Piramal Imaging · 1 drug in Positron emission tomography
Radiomedix · 1 drug in Positron emission tomography
Univ Ca Los Angeles · 1 drug in Positron emission tomography

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Positron emission tomography:

Cite this brief

Drug Landscape (2026). Positron emission tomography — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/positron-emission-tomography. Accessed 2026-06-10.

Positron emission tomography full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing